In the latest issue of BioXconomy, Peter Ronco, President, shares how aligning clinical development strategies with investor expectations through milestone-driven planning, interim data and thoughtful trial design, can reduce risk, provide clearer visibility into progress and strengthen investor confidence and long-term value creation.